MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Perrigo Company plc Retained Earnings 2011-2026 | PRGO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Perrigo Company plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.68 B | -2.25 B | -2.08 B | -2.07 B | -1.93 B | -1.86 B | -1.7 B | -1.84 B | -1.98 B | -2.1 B | 1.94 B | 1.88 B | 1.72 B | 1.31 B | 934 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.94 B | -3.68 B | -913 M |
Quarterly Retained Earnings Perrigo Company plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.26 B | -2.27 B | -2.26 B | -2.25 B | -2.21 B | -2.19 B | -2.08 B | -2.08 B | -2.05 B | -2.06 B | -2.07 B | -2.07 B | -2.04 B | -1.99 B | -1.93 B | -1.93 B | -1.94 B | -1.88 B | -1.82 B | -1.86 B | -1.86 B | -1.86 B | -1.86 B | -1.7 B | -1.7 B | -1.7 B | -1.7 B | -1.84 B | -1.84 B | -1.84 B | -1.84 B | -1.98 B | -1.98 B | -1.98 B | -1.98 B | -2.1 B | -2.1 B | -2.1 B | -2.1 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 2.01 B | 1.96 B | 1.9 B | 1.96 B | 1.72 B | -191 K | 1.72 B | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.01 B | -2.27 B | -1.16 B |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-472 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.42 | 3.01 % | $ 86.3 M |  Canada |
 |
Rockwell Medical
RMTI
|
-397 M | $ 1.04 | 0.97 % | $ 24.3 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
1.06 B | $ 2.62 | 1.55 % | $ 1.39 B | Canada |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 8.21 | 2.43 % | $ 420 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.36 | -0.73 % | $ 3.37 M | Canada |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 2.28 | -2.56 % | $ 2.83 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.35 | 7.03 % | $ 47.1 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-353 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.08 | 1.8 % | $ 1.85 B | Canada |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
-295 M | $ 2.29 | - | $ 309 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 23.49 | 1.25 % | $ 1.09 B | USA |
 |
Evolus
EOLS
|
-661 M | $ 4.37 | -1.35 % | $ 282 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Solid Biosciences
SLDB
|
-958 M | $ 7.23 | 8.23 % | $ 633 M | USA |
 |
Relmada Therapeutics
RLMD
|
-698 M | $ 6.66 | 9.18 % | $ 263 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 6.94 | 4.2 % | $ 4.29 B | Canada |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.38 | 2.99 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
-385 M | $ 0.88 | -2.13 % | $ 43.9 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 13.5 | 1.05 % | $ 16.2 B | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 0.6 | 2.41 % | $ 10.5 M |  China |
 |
cbdMD
YCBD
|
-182 M | $ 0.81 | 4.7 % | $ 3.49 M | USA |
 |
Assertio Holdings
ASRT
|
-703 M | $ 18.57 | 12.48 % | $ 119 M | USA |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.44 | 1.24 % | $ 321 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 0.97 | 1.5 % | $ 104 M | Canada |
 |
Harrow Health
HROW
|
-157 M | $ 36.35 | 3.27 % | $ 1.34 B | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.29 | - | $ 23.9 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |